Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...

Detailed price information for American Tower Corp (AMT-N) from The Globe and Mail including charting and trades.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Rybelsus is now available in over ... with the additional rollout of Wegovy globally. At Novo Nordisk, we will continue to focus on commercial execution, the progression of our R&D pipeline ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk’s first-quarter revenues are likely to have been boosted by the higher sales of Diabetes and Obesity Care products. Diabetes medicines like Ozempic and Rybelsus are expected to have ...

An additional benefit was that Rybelsus could deliver ... In fourth quarter results, Camilla Sylvest, commercial strategy and corporate affairs at Novo Nordisk, stated that GLP-1 sales had ...